Guardant Health Q3 2026 Earnings Call - GUARDANT HEALTH INC

Financial Performance:

• Q3 2026 revenue reached $361 million, a 36% year-over-year increase; Oncology revenue grew 25% to $231 million; Screening revenue surged 180% to $68 million; Biopharma and data revenue rose 8% to $59 million.
• Non-GAAP gross margin expanded to 67% from 66% in the prior year; Non-GAAP operating expenses increased 26% to $287 million due to commercial expansion; Adjusted EBITDA loss narrowed to $37 million (vs. $46 million prior year); Free cash flow burn improved to $37 million (vs. $46 million prior year).
• Quarterly cash and investments totaled $1.1 billion; SHIELD cost per test dropped from $410 to $330, exceeding the year-end target of $350; Target to reach $200 cost per test by end of 2028.
• Oncology test volumes grew 58% to 117,000; SHIELD volumes increased 246% to 83,000; Total platform tests exceed 1.5 million with over 900,000 epigenetic profiles.

Guidance and Future Outlook:

• Raised full-year 2026 revenue guidance to $1.36–$1.37 billion (approx. 38–40% growth); Oncology growth expected at 30% with volume growth >50%; Biopharma growth remains low double-digit; Screening guidance raised to $233–$238 million revenue with 285k–290k tests.
• Full-year 2026 non-GAAP gross margin expected at 65%; Non-GAAP operating expenses projected at $1.105–$1.125 billion (22–24% growth); Free cash flow burn guidance raised to $205–$220 million due to a temporary $10–$15 million CMS claim processing delay for Garden 360 Liquid CDX shifting to 2027.
• Company-wide free cash flow breakeven targeted by end of 2027; Screening standalone cash flow breakeven targeted for end of 2028.

Business Segments and Product Lines:

• Oncology: Garden 360 Liquid volume grew ~30%; Garden 360 Tissue remains the second-fastest growing product; Reveal volume grew >100% driven by MRD and therapy monitoring. Launched Reveal Ultra (sensitivity ≤1 part per million) for biopharma; clinical launch expected year-end.
• Screening: SHIELD revenue up 180% driven by Quest collaboration, DTC campaigns, and ACS guideline inclusion. SHIELD ASPs remained >$800; US coverage expanded to ~100 million people (>80% of eligible CRC population).
• Biopharma and Data: Generated record volumes; secured three new companion diagnostic approvals (31 cumulative globally). Launched Wave 4 Smart Apps for Garden 360 Liquid, including 11 new apps for therapy benefit prediction (e.g., CERD benefit predictor) and lung cancer immunotherapy selection.
• Regulatory: Received FDA approval for Garden 360-CDX as a companion diagnostic for AstraZeneca's Etkima (ESR1 monitoring); Submitted PMA for Garden 360 Tissue; Submitted ADLT application for Garden 360 Liquid CDX with designation expected H1 2027.

Market and Competitive Landscape:

• SHIELD is expanding access through new coverage decisions from UnitedHealthcare, Carillion, eviCore, Emblem Health, and Blue Cross Blue Shield of Kansas City, representing ~30 million new covered lives in one quarter.
• Pennsylvania legislation enacted to expand access to blood-based CRC screening without cost-sharing, signaling a favorable trend ahead of potential USPSTF updates.
• Market sentiment indicates physicians are increasingly adopting ctDNA for real-time treatment monitoring over traditional imaging, particularly for therapy switching and identifying resistance markers.

Risks and Challenges:

• CMS claims processing delay for Garden 360 Liquid CDX due to new billing code implementation, shifting ~$10–$15 million in payments to 2027.
• Continued reliance on commercial infrastructure investment and marketing spend, resulting in elevated operating expenses; ASPs may moderate as the payer mix shifts toward commercially insured patients under age 65.
• Competition in MRD and screening spaces remains intense; Reveal Ultra must maintain performance leadership against emerging tumor-informed whole genome MRD tests.

Management Commentary and Tone:

• Management expressed high confidence ("bullish") regarding the ecosystem's ability to integrate therapy selection, monitoring, and screening, highlighting a "first-of-its-kind" paradigm shift toward blood-based therapy switching.
• Emphasis on "early innings" growth for SHIELD MCD and Reveal Ultra; tone was optimistic about the scalability of the commercial field organization and the impact of Smart Apps.
• Leadership highlighted the strategic advantage of their multimodal data platform (genomics, epigenomics, clinical data) powering the Infinity AI engine for decision support tools.

Analyst Questions and Answers:

• ESR1 Monitoring: Confirmed that the Etkima protocol (quarterly testing) is a key driver for multiple tests per patient; CMS NCD updates are in progress to align reimbursement with quarterly testing frequency.
• SHIELD Seasonality & ASPs: Q3 volume exceeded expectations despite summer seasonality due to rep productivity and Quest collaboration; ASPs >$800 supported by Medicare/MA rates but expected to dip slightly as commercial mix expands, with a $700 floor.
• Reveal Ultra & MRD: Clinical launch of Reveal Ultra expected year-end; strong demand from physicians dissatisfied with first-gen MRD test sensitivity; significant opportunity in therapy monitoring and MRD markets.
• Smart Apps & Volumes: Wave 4 apps apply to a majority of patients, focusing on immunotherapy and therapy prediction; expected to drive volume growth and deepen therapy monitoring attachment rates.
• Garden 360 Tissue: PMA submission received; approval timeline expected ~12 months (H1 2027); anticipated to unlock ADLT pricing upside.
• Political Landscape: No specific impact anticipated from midterm elections; cancer screening viewed as a bipartisan issue with broad support.

Other Key Points:

• Infinity AI now powers decision support tools that summarize patient history and guideline-based options via a conversational agent within the clinical workflow.
• The company has reached 1.5 million patient tests, building a robust real-world evidence base to support regulatory approvals and reimbursement strategies.
• GARDEN360-CDX is the only FDA-approved companion diagnostic for ESR1-targeted therapies, enabling standardized monitoring of ESR1 status evolution.
• The company plans to reinvest incremental gross profit into SHIELD expansion until reaching the 2027 commercial inflection point.